In brief: Acrux, Meditech, Psivida
Tuesday, 03 May, 2005
Melbourne's Acrux (ASX: ACR) has Adam Watkinson as its chief scientific officer. Watkinson is currently manager of drug delivery research and project manager at UK pharmaceutical company ProStrakan .
Meditech Research's (ASX: MTR) Ian Nisbet is to present the company's business plans and product data at the Rodman & Renshaw Global Healthcare Conference in Paris on May 5.
pSivida Limited (ASX:PSD, NASDAQ:PSDV, Xetra:PSI) is to present the interim data from its Phase IIa BrachySil trial in patients with primary liver cancer to the European Society for Therapeutic and Radiation Oncology Conference in Budapest on May 5.
Psivida has reported that both patient cohorts from the Phase IIa trial show the product is safe and effective in prompting tumour regression.The final data is expected to be released in June.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
